This Article Free upon publication Full Text Full Text (PDF) Data Supplement All Versions of this Article: 113/14/1745    most recent CIRCULATIONAHA.105.612630v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O’Donoghue, M. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by O’Donoghue, M. Articles by Braunwald, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATORVASTATIN HEPTANOIC ACID PYRROLE Medline Plus Health Information Heart Attack Related Collections Lipids Acute coronary syndromes

(Circulation. 2006;113:1745-1752.)
© 2006 American Heart Association, Inc.

Coronary Heart Disease

Lipoprotein-Associated Phospholipase A₂ and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial

Michelle O’Donoghue, MD; David A. Morrow, MD, MPH; Marc S. Sabatine, MD, MPH; Sabina A. Murphy, MPH; Carolyn H. McCabe, BS; Christopher P. Cannon, MD; Eugene Braunwald, MD

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.

Correspondence to David A. Morrow, MD, MPH, Brigham and Women’s Hospital, TIMI Study Group, 350 Longwood Ave, First Floor, Boston, MA 02115. E-mail dmorrow{at}partners.org

Received January 25, 2006; revision received March 2, 2006; accepted March 3, 2006.

Background— Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) is associated with the risk of cardiovascular (CV) events in population-based studies. The prognostic value of Lp-PLA₂ in patients with acute coronary syndromes (ACS) has not been established.

Methods and Results— Plasma levels of Lp-PLA₂ activity were measured at baseline (n=3648) and 30 days (n=3265) in patients randomized to atorvastatin 80 mg/d or pravastatin 40 mg/d after ACS in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) trial. The primary end point was death, myocardial infarction, unstable angina, revascularization, or stroke (mean follow-up 24 months). At baseline after ACS, the risk of recurrent CV events was similar across all quintiles of Lp-PLA₂ activity (P_trend=0.88). Overall, mean levels of Lp-PLA₂ were lower at 30 days of follow-up than at baseline (35.7 versus 40.9 nmol · min^–1 · mL^–1, P<0.001). In particular, treatment with atorvastatin 80 mg/d was associated with a 20% reduction in Lp-PLA₂ activity (P<0.001), whereas Lp-PLA₂ rose 3.6% with pravastatin 40 mg/d (P<0.001). Patients with 30-day Lp-PLA₂ activity in the highest quintile were at significantly increased risk of recurrent CV events compared with those in the lowest quintile (26.4% versus 17.6%, P_trend=0.002). After adjustment for cardiac risk factors, treatments, achieved low-density lipoprotein (LDL), and C-reactive protein, Lp-PLA₂ activity in the highest quintile remained independently associated with a higher risk of recurrent CV events (adjusted hazard ratio 1.33, 95% confidence interval [CI] 1.01 to 1.74).

Conclusions— Lp-PLA₂ is not useful for risk stratification when measured early after ACS. At 30 days, Lp-PLA₂ activity is significantly lowered with high-dose statin therapy and is associated with an increased risk of CV events independent of C-reactive protein and LDL cholesterol levels.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				M. S.V. Elkind, V. Leon, Y. P. Moon, M. C. Paik, and R. L. Sacco High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 Stability Before and After Stroke and Myocardial Infarction Stroke, October 1, 2009; 40(10): 3233 - 3237. [Abstract] [Full Text] [PDF]

				S. U. Eisenhardt, J. Habersberger, A. Murphy, Y.-C. Chen, K. J. Woollard, N. Bassler, H. Qian, C. von zur Muhlen, C. E. Hagemeyer, I. Ahrens, et al. Dissociation of Pentameric to Monomeric C-Reactive Protein on Activated Platelets Localizes Inflammation to Atherosclerotic Plaques Circ. Res., July 17, 2009; 105(2): 128 - 137. [Abstract] [Full Text] [PDF]

				S. Tsimikas, J. Willeit, M. Knoflach, M. Mayr, G. Egger, M. Notdurfter, J. L. Witztum, C. J. Wiedermann, Q. Xu, and S. Kiechl Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study Eur. Heart J., January 1, 2009; 30(1): 107 - 115. [Abstract] [Full Text] [PDF]

				E. S. Brilakis, A. Khera, B. Saeed, S. Banerjee, D. K. McGuire, S. A. Murphy, and J. A. de Lemos Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Coronary and Aortic Atherosclerosis: Findings from the Dallas Heart Study Clin. Chem., December 1, 2008; 54(12): 1975 - 1981. [Abstract] [Full Text] [PDF]

				S. M. Boekholdt, R. J. de Winter, and J. J.P. Kastelein Inhibition of Lipoprotein-Associated Phospholipase Activity by Darapladib: Shifting Gears in Cardiovascular Drug Development: Are Antiinflammatory Drugs the Next Frontier? Circulation, September 9, 2008; 118(11): 1120 - 1122. [Full Text] [PDF]

				P. W. Serruys, H. M. Garcia-Garcia, P. Buszman, P. Erne, S. Verheye, M. Aschermann, H. Duckers, O. Bleie, D. Dudek, H. E. Botker, et al. Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque Circulation, September 9, 2008; 118(11): 1172 - 1182. [Abstract] [Full Text] [PDF]

				S. J. Robins, D. Collins, J. J. Nelson, H. E. Bloomfield, and B. F. Asztalos Cardiovascular Events With Increased Lipoprotein-Associated Phospholipase A2 and Low High-Density Lipoprotein-Cholesterol: The Veterans Affairs HDL Intervention Trial Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1172 - 1178. [Abstract] [Full Text] [PDF]

				D. Mannheim, J. Herrmann, D. Versari, M. Gossl, F. B. Meyer, J. P. McConnell, L. O. Lerman, and A. Lerman Enhanced Expression of Lp-PLA2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques Stroke, May 1, 2008; 39(5): 1448 - 1455. [Abstract] [Full Text] [PDF]

				S. Wassertheil-Smoller, C. Kooperberg, A. P. McGinn, R. C. Kaplan, J. Hsia, S. L. Hendrix, J. E. Manson, J. S. Berger, L. H. Kuller, M. A. Allison, et al. Lipoprotein-Associated Phospholipase A2, Hormone Use, and the Risk of Ischemic Stroke in Postmenopausal Women Hypertension, April 1, 2008; 51(4): 1115 - 1122. [Abstract] [Full Text] [PDF]

				M. S. Sabatine, D. A. Morrow, M. O'Donoghue, K. A. Jablonksi, M. M. Rice, S. Solomon, Y. Rosenberg, M. J. Domanski, J. Hsia, and for the PEACE Investigators Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2463 - 2469. [Abstract] [Full Text] [PDF]

				R. P. Giugliano and E. Braunwald The Year in Non ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1386 - 1395. [Full Text] [PDF]

				V. G. Saougos, A. P. Tambaki, M. Kalogirou, M. Kostapanos, I. F. Gazi, R. L. Wolfert, M. Elisaf, and A. D. Tselepis Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2 Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2236 - 2243. [Abstract] [Full Text] [PDF]

				M. Persson, B. Hedblad, J. J. Nelson, and G. Berglund Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1411 - 1416. [Abstract] [Full Text] [PDF]

				S. Lavi, J. P. McConnell, C. S. Rihal, A. Prasad, V. Mathew, L. O. Lerman, and A. Lerman Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans Circulation, May 29, 2007; 115(21): 2715 - 2721. [Abstract] [Full Text] [PDF]

				C. A. Garza, V. M. Montori, J. P. McConnell, V. K. Somers, I. J. Kullo, and F. Lopez-Jimenez Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic Review Mayo Clin. Proc., February 1, 2007; 82(2): 159 - 165. [Abstract] [Full Text] [PDF]

				W. Koenig and N. Khuseyinova Biomarkers of Atherosclerotic Plaque Instability and Rupture Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 15 - 26. [Abstract] [Full Text] [PDF]

				N. S. Jenny Lipoprotein-associated phospholipase A2: novel biomarker and causal mediator of atherosclerosis? Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2417 - 2418. [Full Text] [PDF]

				Y. Gerber, J. P. McConnell, A. S. Jaffe, S. A. Weston, J. M. Killian, and V. L. Roger Lipoprotein-Associated Phospholipase A2 and Prognosis After Myocardial Infarction in the Community Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2517 - 2522. [Abstract] [Full Text] [PDF]

				F. D. Kolodgie, A. P. Burke, K. S. Skorija, E. Ladich, R. Kutys, A. T. Makuria, and R. Virmani Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2523 - 2529. [Abstract] [Full Text] [PDF]

				M. S. V. Elkind, W. Tai, K. Coates, M. C. Paik, and R. L. Sacco High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med, October 23, 2006; 166(19): 2073 - 2080. [Abstract] [Full Text] [PDF]

				A. Zalewski, J. J. Nelson, L. Hegg, and C. Macphee Lp-PLA2: A New Kid on the Block Clin. Chem., September 1, 2006; 52(9): 1645 - 1650. [Abstract] [Full Text] [PDF]